Quarterly report pursuant to Section 13 or 15(d)

Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Diluted Earnings Per Share (Details)

v3.19.3
Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Diluted Earnings Per Share (Details) - shares
9 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Antidilutive securities excluded from computation of diluted weighted shares outstanding 24,291,868 21,628,285
Stock Options and Restricted Stock Awards - PAVmed Inc. 2014 Equity Plan [Member]    
Antidilutive securities excluded from computation of diluted weighted shares outstanding 5,853,529 3,277,140
Unit Purchase Options - "UPO-Z" /"UPO-W" - as to Shares of common stock [Member]    
Antidilutive securities excluded from computation of diluted weighted shares outstanding 53,000 53,000
Unit Purchase Options - "UPO-Z" - as to Shares Underlying Series Z Warrants [Member]    
Antidilutive securities excluded from computation of diluted weighted shares outstanding 53,000 53,000
Series Z Warrants [Member]    
Antidilutive securities excluded from computation of diluted weighted shares outstanding 16,815,039 16,815,039
Series W Warrants [Member]    
Antidilutive securities excluded from computation of diluted weighted shares outstanding 381,818 381,818
Series S Warrants [Member]    
Antidilutive securities excluded from computation of diluted weighted shares outstanding [1] 1,199,383
Series B Convertible Preferred Stock [Member]    
Antidilutive securities excluded from computation of diluted weighted shares outstanding 1,135,482 1,048,288
[1] The Series S Warrants were not included in weighted average shares outstanding in the three and nine months ended September 30, 2018 due to certain restrictions on beneficial ownership of the Holder which had not lapsed until January 2019.